When something is going wrong in your body, there will be signs. They may be subtle, but they are visible in close observation. If you are a smoker, you may be worried about the smell of smoke emanating from your mouth or clothes. However, there are other signs that tell whether you smoke or not and these signs are difficult to get rid of!

Smoking is the harmful act of inhaling tobacco infused smoke and is a common activity all over the world. According to the Center of Disease Control and Prevention (CDC), over 480,000 deaths happen each year due to smoking or smoke inhalation. The organization explained that smoking causes harm to nearly all organs and quitting lowers the risk of early death and other smoking related diseases.

Like many other substances, there are clear tell-tale signs when someone is smoking. This is especially important for finding lung problems like Chronic obstructive pulmonary disease (COPD), which is a lung disease that makes it hard to breathe, sooner so people can get help.

Why Does Smoking Affect Your Physical Appearance?

Action on Smoking and Health (ASH) explains that tobacco smoke has more than 7,000 harmful chemicals like nicotine, carbon monoxide, and various metals like arsenic, cadmium, and lead, quickly reach your lungs and then travel through your blood to all your organs, including your skin. Smoking damages your skin's ability to heal because it increases an enzyme metalloproteinase (MMPs) that breaks down collagen. Collagen is what keeps your skin smooth and elastic. As you lose collagen, your skin sags. Squinting from the smoke and puckering your mouth when smoking also cause wrinkles around your eyes and mouth.

Smoking also reduces blood flow to your skin, which means it gets less oxygen and nutrients. All these things together lead to what doctors call a "smoker's face." Quitting smoking can help prevent or slow down these skin problems."

Visible Signs Of Smoking

Here are some visible signs of smoking in people, according to 2013, Lung India

Fingers and Nails

When people smoke, the tar and other chemicals in the smoke stick to their fingers and nails. This repeated contact causes a yellow stain that's hard to wash off. It's a very common sign that someone regularly handles cigarettes or biris.

Moustaches

Especially in older people with white moustaches, smoking causes a yellowing effect. This is most noticeable in the center of the moustache, where the smoke from the nose directly hits the hair. The consistent exposure to smoke colors the hair over time.

Lips

Heavy smokers often have a bluish-black tint to their lips. This discoloration happens because the chemicals in tobacco smoke affect the blood flow and the color of the skin on the lips. The constant exposure changes the lip's natural color.

Teeth

Smoking causes teeth to stain both inside and out. The outside of the teeth turns yellow from the tar, while the inside develops a brownish-black stain. This happens because the smoke seeps into the enamel and discolors the teeth over time.

Premature Wrinkling

Smoking makes the skin age faster. This leads to wrinkles like "crow's feet" around the eyes and "cobblestone wrinkles" on the neck. This happens because smoking reduces blood flow, limiting oxygen to the skin, and damages collagen, which keeps skin elastic.

Nodular Elastosis

This condition, also known as "Favre–Racouchot syndrome," causes blackheads and wrinkles, especially around the eyes and temples. It is made worse by both sun exposure and heavy smoking. The skin becomes discolored with visible nodules and wrinkles.

Facial Wrinkling and COPD

A study published in Thorax 2006 found a connection between wrinkles on the face and COPD, a lung disease. It's thought that smoking affects both the skin and lungs through similar processes. If doctors notice signs like "crow's feet" on a smoker's face, they might recommend tests for COPD. This early detection can help people get treatment sooner and improve their lung health.

While research shows women need more sleep than men due to brain function, hormones, and multitasking, females around the globe are struggling to get enough sleep, according to experts.

A 2016 study by the Sleep Research Centre at the UK’s Loughborough University found that women needed 20 minutes more sleep because of multitasking and performing more complex brain tasks during the day.

But, the American Academy of Sleep Medicine (AASM), revealed that an estimated 30 percent of women fail to get sufficient sleep.

Hormones, mood disorders, and caregiving responsibilities, coupled with professional pressures and stress, are the major reasons driving up insomnia and other sleep issues among women.

“Women around the world face a higher burden of sleep difficulties because their sleep cycles are tightly interlinked with hormonal shifts that occur throughout life,” Dr. Janhvi Siroya Shah, Sleep Specialist from the University of Bern, Switzerland, told HealthandMe.

Gender Gap In Sleep: Why Women Sleep Less

The gender gap in sleep is real, as revealed by the recent ResMed Global Sleep Survey 2026, which showed that 56 percent of women get a good night's sleep only four days or fewer per week, compared to 50 percent of men.

Women were also 48 percent more likely to report problems falling asleep than men (42 percent). More than 50 percent of women felt waking up not feeling rested for 1-2 nights per week or more, compared to 46 percent of men.

The study flagged stress or anxiety as the biggest barrier to consistent, quality sleep (39 per cent), followed by work-related responsibilities (37 per cent) and household duties (31 per cent) among women.

Speaking to HealthandMe, Dr. Kirti Kadian, from the Department of Pulmonary Critical Care & Sleep Medicine at AIIMS Bhopal, said: “Women experience disproportionate sleep challenges globally, largely because their bodies undergo repeated physiological transitions that influence how sleep is regulated.”

The experts cited the main reasons as

• fluctuations during menstruation,
• pregnancy,
• postpartum recovery
• menopause.

All these factors can alter mood regulation, increase nighttime alertness, and disrupt the architecture of sleep itself.

Dr Kadian said that hormonal fluctuations across the life course -- especially during the menopausal transition -- can affect circadian rhythm, airway stability, pain sensitivity, and the nervous system’s response to stress.

“When these biological changes coincide with external stressors, such as multitasking, emotional labor or caregiving demands, women become far more vulnerable to insomnia and unrefreshing sleep,” Shah said.

The prevalence of sleep disorders increases from about 16–42 percent in pre-menopause to around 39–47 percent in peri-menopause and up to 35–69 percent in post-menopause, indicating that sleep disturbances become more common as women progress through different reproductive stages.

“Declining levels of estrogen and progesterone can disrupt the body’s sleep regulation and trigger symptoms like hot flashes and night sweats, while reduced melatonin may make it harder to fall and stay asleep,” Dr. Kadian explained.

In addition, certain medical conditions that are more common in women, such as thyroid disorders, anemia, and autoimmune diseases, can also negatively affect sleep and overall health.

How Poor Sleep Affects Women

Poor sleep also significantly affects both physical and mental health, increasing the risk of

• metabolic disorders,
• cardiovascular disease,
• weakened immunity,
• persistent fatigue,
• reduced concentration,
• irritability,
• anxiety,
• depression.

How Women can Improve their Sleep

The Harvard Medical School suggested that to get a better sleep cycle women should:

• Create a sleep sanctuary by removing the television, computer, smartphone or tablet, from the bedroom.
• Cut down or limit afternoon naps to 20 to 30 minutes
• Avoid caffeine after noon
• Get regular exercise, but not within three hours of bedtime.

While early-stage research raised hopes of oral semaglutide (GLP-1 pill) slowing down the progression of Alzheimer’s disease, results of a new large-scale clinical trial have rendered it ineffective.

Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries -- showed that semaglutide led to no significant difference after two years.

The findings, published in the Lancet journal, however, revealed that the popular weight loss drug can lead to significant reductions in several biological markers of Alzheimer’s disease.

Yet, it did not help slow the progression of the neurodegenerative disease, said an international team of researchers, including those from the University of California-San Diego.

"Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease," they said in the paper.

"Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications," the team added.

The EVOKE and EVOKE+ trials

The studies are the first major phase 3 trials to investigate this possibility in people with early Alzheimer’s disease.

The researchers conducted the trial on about 3,800 patients aged 55-85 years. The patients received either up to 14 mg of oral semaglutide daily or a placebo pill.

After two years, no significant difference was seen in slowing down the cognitive disease's progression in patients taking semaglutide and patients taking the placebo.

"The results of the large evoke(+) trials do not support the efficacy of 14 mg/day of semaglutide given for up to 156 weeks in participants with biomarker-confirmed Alzheimer's disease in the MCI or mild dementia stage," the researchers said.

While “GLP-1 [drugs] have given us so many wonderful results," the trial results are "disappointing,” and “a setback for the field”, endocrinologist Daniel Drucker was quoted as saying to the Scientific American.

Drucker says there are many potential explanations why oral semaglutide didn’t work as hoped. The fatty-acid structure surrounding semaglutide might have prevented it from being able to penetrate certain brain regions, such as the hippocampus, which controls memory and cognitive function.

What Is Alzheimer’s Disease

Alzheimer's disease is a progressive neurodegenerative disease characterised by gradual cognitive and functional decline.

It is one of the most common forms of dementia and mostly affects adults over the age of 65.

Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.

The disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate and damage cells responsible for memory.

Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Other signs include:

• losing or misplacing things
• getting lost when walking or driving
• being confused, even in familiar places
• losing track of time
• difficulties solving problems or making decisions
• difficulties performing familiar tasks
• misjudging distances to objects visually.

In the year 1947, on the remote Scottish island of Jura, George Orwell sat hunched over a typewriter in a farmhouse, engaged in a desperate race against time to finish his masterpiece, 1984, while a ‘slow-motion plague’ consumed his lungs.

The man who was born in Motihari, Bihar, was suffering from tuberculosis. He would cough up blood and frequently collapse out of sheer exhaustion, even as he typed the final warnings of a dystopian future. He finished the book in December 1948 and died just over a year later.

Orwell’s story is a haunting reminder that TB has always been a disease of the displaced. As we approach World Tuberculosis Day this year with the theme ‘Yes! We Can End TB: Led by countries, powered by people, we face a sobering reality.

We have the modern tools that Orwell lacked, but the global narrative remains trapped in an outdated cycle where technological potential far outstrips operational reality. To end this disease, we must stop viewing TB through a narrow clinical lens and start addressing the systemic inefficiencies that leave out millions.

From Years to Months: The Scientific Revolution

For decades, a diagnosis of drug-resistant TB (DR-TB) was a near-death sentence even with treatment. Patients faced a grueling 18 to 24-month treatment regimen involving thousands of pills and daily painful injections that often caused permanent side effects like deafness.

With the introduction of the BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin), this tide seems to have turned. The all-oral four-drug treatment, touted as a medical miracle, has slashed recovery time for drug-resistant strains to just six months.

However, even a magic pill cannot overcome a broken system. We must distinguish between clinical success and social success. A patient might technically be cured of the bacteria, but if they lose their job or suffer from social stigma during those six months, the system has still failed them.

The Gender Gap: Why Men Remain Elusive

Statistically, men bear a higher burden of TB, yet they are often the hardest to bring into the care net. According to the World Health Organization (WHO), men account for approximately 55 per cent of all TB cases globally, compared to 33 per cent for women and 12 per cent for children.

This is not a biological accident; it is a structural failure. Gendered social norms often prevent men from seeking care until the disease is advanced. As primary earners, the prospect of losing wages – combined with the stigma of diagnosis – creates a powerful disincentive to visit a clinic. To be truly people-centered, we must move away from static clinic hours and towards flexible, community-based care that reaches men at places where they work.

The Silo System and the Economic Reality

Treating TB in isolation is an outdated strategy. We see patients suffering from a double burden because TB is usually accompanied by diabetes, malnutrition, or even HIV.

• Diabetes: Increases the risk of TB by two to three times.
• HIV: People living with HIV are 16 times more likely to fall ill with TB.

Despite this, our medical systems remain stubbornly reserved. A patient is often forced to navigate fragmented clinics that rarely communicate. Integration is the only way to ensure we treat the whole person, not just the pathogen.

The Human Cost of Cure

The path forward requires us to acknowledge that we cannot end TB by looking only at the lungs; we must look at the lives of those affected. The end of TB is a matter of leadership and courage to fix the systems that hold medical science back.

As we look towards World Tuberculosis Day, let us not just renew our commitments; let us hold our systems to account. The human cost of cure is currently too high, not because of the medicine, but because of the world in which the medicine is delivered.

As we honor World Tuberculosis Day, let us ensure that no one else has to choose between finishing their life’s work and surviving a curable disease. Curing tuberculosis is no longer a biological mystery; it is a test of our collective humanity.